The cell and gene therapy CROs market is anticipated to grow at an annualized rate of 18% by 2035, claims Roots Analysis Characterized by high prevalence rate of rare and genetic disorders, and rise in demand for effective novel ATMPs, the cell and gene therapy contract research industry is likely to witness evolutionary advancements, in the coming years. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html